tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Value
New
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News WireArrivedEquityMultiple
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Smart Value
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

JNCE

Voyager Therapeutics appoints Jacquelyn Fahey Sandell as CLO
The FlyVoyager Therapeutics appoints Jacquelyn Fahey Sandell as CLO
2y ago
JNCE
VYGR
Atea Pharmaceuticals Surges Over on Potential Takeover Bid
PremiumMarket News
Atea Pharmaceuticals Surges Over on Potential Takeover Bid
2y ago
AVIR
JNCE
Jounce Therapeutics (JNCE) Q1 Earnings Cheat Sheet
PremiumPre-Earnings
Jounce Therapeutics (JNCE) Q1 Earnings Cheat Sheet
2y ago
JNCE
Biotech Alert: Searches spiking for these stocks today
PremiumThe Fly
Biotech Alert: Searches spiking for these stocks today
2y ago
UBX
CYCN
Buyout Offer Sends Jounce Jumping 20%
PremiumMarket News
Buyout Offer Sends Jounce Jumping 20%
2y ago
JNCE
Jounce Therapeutics downgraded to Neutral from Overweight at Piper Sandler
PremiumThe FlyJounce Therapeutics downgraded to Neutral from Overweight at Piper Sandler
2y ago
JNCE
Jounce Therapeutics implements workforce reduction of 84% of employees
Premium
The Fly
Jounce Therapeutics implements workforce reduction of 84% of employees
2y ago
JNCE
Jounce to be acquired by Concentra for $1.85 in cash per share plus CVR
Premium
The Fly
Jounce to be acquired by Concentra for $1.85 in cash per share plus CVR
2y ago
JNCE
Jounce: Patients from ovarian cancer combo cohort study had durable responses
PremiumThe Fly
Jounce: Patients from ovarian cancer combo cohort study had durable responses
2y ago
JNCE
Biotech Alert: Searches spiking for these stocks today
PremiumThe Fly
Biotech Alert: Searches spiking for these stocks today
2y ago
CDMO
CRBP
JNCE Soars on Concentra’s $1.8 Per Share Bid
PremiumMarket News
JNCE Soars on Concentra’s $1.8 Per Share Bid
2y ago
JNCE
Jounce Therapeutics confirms receipt of acquisition proposal from Concentra
PremiumThe Fly
Jounce Therapeutics confirms receipt of acquisition proposal from Concentra
2y ago
JNCE
Jounce Therapeutics confirms unsolicited proposal from Concentra Biosciences
PremiumThe FlyJounce Therapeutics confirms unsolicited proposal from Concentra Biosciences
2y ago
JNCE
Jounce Therapeutics downgraded to Neutral from Outperform at SMBC Nikko
Premium
The Fly
Jounce Therapeutics downgraded to Neutral from Outperform at SMBC Nikko
2y ago
JNCE
Jounce, Redx Pharma announce recommended all share merger transaction
Premium
The Fly
Jounce, Redx Pharma announce recommended all share merger transaction
2y ago
JNCE
Jounce downgraded to Market Perform from Outperform at Raymond James
PremiumThe Fly
Jounce downgraded to Market Perform from Outperform at Raymond James
2y ago
JNCE
Jounce Therapeutics to reduce workforce by 57%
PremiumThe Fly
Jounce Therapeutics to reduce workforce by 57%
2y ago
JNCE
Piper Sandler keeps Overweight on Jounce Therapeutics, lowers price target to $5
PremiumThe Fly
Piper Sandler keeps Overweight on Jounce Therapeutics, lowers price target to $5
2y ago
GILD
JNCE
Biotech Alert: Searches spiking for these stocks today
PremiumThe Fly
Biotech Alert: Searches spiking for these stocks today
2y ago
GILD
HOTH
After-Hours Movers 
PremiumThe FlyAfter-Hours Movers 
2y ago
CLNN
ISEE
Gilead to buy remaining rights for GS-1811 from Jounce Therapeutics for $67M
Premium
The Fly
Gilead to buy remaining rights for GS-1811 from Jounce Therapeutics for $67M
2y ago
GILD
JNCE
Jounce Therapeutics presents INNATE Phase 1, SELECT trial data
Premium
The Fly
Jounce Therapeutics presents INNATE Phase 1, SELECT trial data
2y ago
JNCE

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >